Maze Therapeutics Inc (MAZE)

Currency in USD
26.50
+0.81(+3.15%)
Closed·
26.74+0.24(+0.91%)
·
Unusual trading volume
MAZE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
26.0029.09
52 wk Range
7.1653.65
Key Statistics
Prev. Close
26.5
Open
27.33
Day's Range
26-29.09
52 wk Range
7.16-53.65
Volume
2.22M
Average Volume (3m)
864.5K
1-Year Change
184.787%
Book Value / Share
7.38
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MAZE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
64.45
Upside
+143.22%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Maze Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Compare MAZE to Peers and Sector

Metrics to compare
MAZE
Peers
Sector
Relationship
P/E Ratio
−10.0x−6.6x−0.5x
PEG Ratio
0.03−0.010.00
Price/Book
3.7x2.3x2.6x
Price / LTM Sales
-0.0x3.2x
Upside (Analyst Target)
118.9%269.3%45.2%
Fair Value Upside
Unlock7.0%6.4%Unlock

Analyst Ratings

12 Buy
0 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 64.45
(+143.22% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy110.00+315.09%-MaintainApr 14, 2026
Truist Securities
Buy64.00+141.51%68.00MaintainApr 13, 2026
JPMorgan
Buy58.00+118.87%52.00MaintainMar 31, 2026
TD Cowen
Buy---MaintainMar 25, 2026
BTIG
Buy46.00+73.58%-MaintainMar 25, 2026

Earnings

Latest Release
Mar 25, 2026
EPS / Forecast
-0.65 / -0.63
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

MAZE Income Statement

People Also Watch

25.89
ALMS
+3.64%
115.99
ABVX
+4.09%
26.94
TNGX
-2.99%
52.840
TERN
-0.04%
10.77
ORIC
+1.32%

FAQ

What Is the Maze Therapeutics (MAZE) Stock Price Today?

The Maze Therapeutics stock price today is 26.50 USD.

What Stock Exchange Does Maze Therapeutics Trade On?

Maze Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Maze Therapeutics?

The stock symbol for Maze Therapeutics is "MAZE."

What Is the Maze Therapeutics Market Cap?

As of today, Maze Therapeutics market cap is 1.32B USD.

What Is Maze Therapeutics's Earnings Per Share (TTM)?

The Maze Therapeutics EPS (TTM) is -3.05.

When Is the Next Maze Therapeutics Earnings Date?

Maze Therapeutics will release its next earnings report on May 20, 2026.

From a Technical Analysis Perspective, Is MAZE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Maze Therapeutics Stock Split?

Maze Therapeutics has split 0 times.

How Many Employees Does Maze Therapeutics Have?

Maze Therapeutics has 141 employees.

What is the current trading status of Maze Therapeutics (MAZE)?

As of Apr 23, 2026, Maze Therapeutics (MAZE) is trading at a price of 26.50 USD, with a previous close of 26.50 USD. The stock has fluctuated within a day range of 26.00 USD to 29.09 USD, while its 52-week range spans from 7.16 USD to 53.65 USD.

What Is Maze Therapeutics (MAZE) Price Target According to Analysts?

The average 12-month price target for Maze Therapeutics is 64.45 USD, with a high estimate of 110 USD and a low estimate of 46 USD. 12 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +143.22% Upside potential.

What Is the MAZE After Hours Price?

MAZE's last after hours stock price is 26.74 USD, the stock has decreased by 0.24, or 0.91%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.